drugset / Trial / NCT00402545
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 1
Completed
29 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabBristol-Myers Squibb · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of this regimen of 4 drugs and the tumor response.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fluorouracil | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |